Results 81 to 90 of about 18,617,874 (263)

Beyond Visual Scoring: Computational Computed Tomography Analysis for High‐Resolution Computed Tomography–Based Quantification of Interstitial Lung Disease in Inflammatory Rheumatic Disease

open access: yesArthritis Care &Research, EarlyView.
Interstitial lung disease (ILD) is a significant cause of morbidity and mortality in patients with inflammatory rheumatic disorders (IRDs). High‐resolution computed tomography (HRCT) is widely considered the gold standard for the noninvasive assessment of ILD; however, its interpretation is constrained by substantial interobserver variability and the ...
Alexander Pfeil   +7 more
wiley   +1 more source

The effect of an open-label placebo on the late positive potential and intensity rating of angry-face images

open access: yes, 2022
Placebos sind inerte Substanzen oder Behandlungen, die durch Suggestionen zu einer positiven Wirkung führen können. Diese Wirkung zeigt sich auch, wenn Personen wissen, dass sie ein Placebo erhalten.
Wallner, Sarah
core   +1 more source

Nocebo effects by providing informed consent in shared decision making? Not necessarily: a randomized pilot-trial using an open-label placebo approach

open access: yesBMC Medical Ethics, 2020
Background Thorough information of the patient is an integral part of the process of shared decision making. We aimed to investigate if detailed information about medication may induce nocebo (or placebo) effects.
Fabian Holzhüter, Johannes Hamann
doaj   +1 more source

Elevated Liver Enzymes Is Not an Impediment to Allopurinol Dose Escalation: An Observational Cohort Study

open access: yesArthritis Care &Research, EarlyView.
Objective Routine liver enzyme monitoring is advocated for while on allopurinol, but supporting guidance is lacking. We assessed the incidence and factors associated with elevated liver enzyme levels in patients with gout commenced on allopurinol. Methods One hundred and fifty patients with gout and normal baseline serum aminotransferases initiated on ...
May Shuen Tang   +4 more
wiley   +1 more source

Early start of opicapone in Parkinson’s disease: evidence from a pooled analysis of phase 3 trials for sustained benefit in patients with recent onset of motor fluctuations

open access: yesFrontiers in Neurology
BackgroundLevodopa is the mainstay of Parkinson’s disease (PD) therapy, but its long-term use is often complicated by the development of motor fluctuations.
Joaquim J. Ferreira   +17 more
doaj   +1 more source

Real‐World Effectiveness and Safety of Secukinumab in Giant Cell Arteritis: An Italian Multicenter Cohort Study

open access: yesArthritis Care &Research, EarlyView.
Objective The objective of this study was to evaluate the real‐world effectiveness and safety of secukinumab in patients with giant cell arteritis (GCA). Methods This multicenter retrospective study included patients with GCA who received secukinumab at 14 Italian centers with at least six months of follow‐up.
Luca Iorio   +28 more
wiley   +1 more source

The role of patient beliefs in open-label placebo effects.

open access: yesHealth Psychology, 2019
Recent research on open-label placebos, or placebos administered without deception or concealment, suggests that they can be effective in a variety of conditions. The current research sought to unpack the mechanisms underlying the treatment efficacy of open-label placebos.A health care provider induced an allergic reaction in 148 participants via a ...
Kari A. Leibowitz   +3 more
openaire   +3 more sources

Real‐World Safety of Concomitant Colchicine and Statin Therapy

open access: yesArthritis Care &Research, EarlyView.
Objective This study aimed to evaluate the risk of clinically meaningful muscle‐ and liver‐related outcomes associated with concomitant colchicine–statin therapy in a real‐world setting, and to determine whether concomitant therapy increases the incidence of toxicity compared with either agent alone.
Roni Meidan   +5 more
wiley   +1 more source

Response to eculizumab in patients with myasthenia gravis recently treated with chronic IVIg: a subgroup analysis of REGAIN and its open-label extension study

open access: yesTherapeutic Advances in Neurological Disorders, 2020
Background: In the phase III eculizumab for refractory generalized myasthenia gravis REGAIN study [ClinicalTrials.gov identifier: NCT01997229] and its open-label extension (OLE) [ClinicalTrials.gov identifier: NCT02301624], patients with treatment ...
Saiju Jacob   +7 more
doaj   +1 more source

Oral glucocorticoids added to ILD‐modifying therapy in systemic sclerosis‐associated interstitial lung disease: a target trial emulation study from the EUSTAR database.

open access: yesArthritis Care &Research, Accepted Article.
Objectives We aimed to estimate whether adding oral glucocorticoids to ILD‐modifying therapy improves 12‐month lung outcomes in systemic sclerosis‐associated interstitial lung disease (SSc‐ILD). Methods We emulated a target trial using the EUSTAR database.
Zubeyir Salis   +14 more
wiley   +1 more source

Home - About - Disclaimer - Privacy